Ocata Therapeutics Inc fka OCAT

[rocky301]

thanks cty, so far the sites seem to be following the November Executive summary somewhat. Note Jules Stein was only one listed for both trials and probably indicated lead clinic(I missed that) and now Casey coming in under Stargardts. I had figured Casey for the lead but had no doubt about their participation.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62263635

Filed IND for treatment of Stargardt’s disease ? IND was approved by FDA on 19 November 2010. ? IRB has approved protocol - Anticipate commencing patient treatment in 1Q2011. ? Designated trial sites: Jules Stein Eye Institute (UCLA); Casey Eye Institute (Oregon Health Sciences University); University of Massachusetts Memorial Medical Center; New Jersey Medical School.

? Filed IND for treatment of Dry AMD on 26 November 2010 ? Anticipate FDA approval and first patient treatment in second half of 2011. ? Designated trial sites: Jules Stein Eye Institute (UCLA); Stanford University School of Medicine; and the Edward S. Harness Eye Institute (Columbia University College of Physicians and Surgeons).
http://www.advancedcell.com/documents/Executive_Summary-ACT_RPE_Program.pdf